中国合理用药探索2025，Vol.22Issue(4)：28-32,5.DOI:10.3969/j.issn.2096-3327.2025.04.004
艾立布林联合卡培他滨治疗晚期三阴性乳腺癌的临床疗效及安全性
Efficacy and Safety of Eribulin in Combination with Capecitabine in the Treatment of Advanced Triple-Negative Breast Cancer
郭广成 1段馨 1王楠1
作者信息
- 1. 郑州大学第一附属医院乳腺外二科,郑州 450052
- 折叠
摘要
Abstract
Objective:To explore the clinical efficacy and safety of eribulin monotherapy and in combination with capecitabine in patients with advanced triple-negative breast cancer(TNBC).Methods:A total of 83 patients with advanced TNBC treated in a hospital from February 2022 to May 2023 were selected and divided into the monotherapy group(n=28)and the combination therapy group(n=55).Patients in the monotherapy group received eribulin mesilate injection,while patients in the combination therapy group received capecitabine tablets on the basis of the monotherapy group were treated for 4 cycles.The clinical efficacy,progression free survival(PFS)and incidence of adverse reactions were compared between the two groups.Results:No statistically significant differences were observed in objective response rate and disease control rate between the two groups(P>0.05).The median PFS in the combination therapy group was higher than that in the monotherapy group(P=0.001).No statistically significant difference was found in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of eribulin and capecitabine in the treatment of patients with advanced TNBC results in a longer median PFS compared to eribulin monotherapy,without increasing the risk of adverse reactions.关键词
艾立布林/卡培他滨/晚期三阴性乳腺癌/临床疗效/安全性Key words
eribulin/capecitabine/advanced triple-negative breast cancer/clinical effect/safety分类
临床医学引用本文复制引用
郭广成,段馨,王楠..艾立布林联合卡培他滨治疗晚期三阴性乳腺癌的临床疗效及安全性[J].中国合理用药探索,2025,22(4):28-32,5.
